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Synaptophysin depletion and intraneuronal
Aβ in organotypic hippocampal slice
cultures from huAPP transgenic mice
Claire S. Harwell1 and Michael P. Coleman1,2*
Abstract
Background: To date, there are no effective disease-modifying treatments for Alzheimer’s disease (AD). In order to
develop new therapeutics for stages where they are most likely to be effective, it is important to identify the first
pathological alterations in the disease cascade. Changes in Aβ concentration have long been reported as one of
the first steps, but understanding the source, and earliest consequences, of pathology requires a model system that
represents all major CNS cell types, is amenable to repeated observation and sampling, and can be readily
manipulated. In this regard, long term organotypic hippocampal slice cultures (OHSCs) from neonatal amyloid mice
offer an excellent compromise between in vivo and primary culture studies, largely retaining the cellular
composition and neuronal architecture of the in vivo hippocampus, but with the in vitro advantages of accessibility
to live imaging, sampling and intervention.
Results: Here, we report the development and characterisation of progressive pathological changes in an
organotypic model from TgCRND8 mice. Aβ1-40 and Aβ1-42 rise progressively in transgenic slice culture medium and
stabilise when regular feeding balances continued production. In contrast, intraneuronal Aβ continues to
accumulate in close correlation with a specific decline in presynaptic proteins and puncta. Plaque pathology is not
evident even when Aβ1-42 is increased by pharmacological manipulation (using calpain inhibitor 1), indicating that
soluble Aβ species, or other APP processing products, are sufficient to cause the initial synaptic changes.
Conclusions: Organotypic brain slices from TgCRND8 mice represent an important new system for understanding
mechanisms of Aβ generation, release and progressive toxicity. The pathology observed in these cultures will allow
for rapid assessment of disease modifying compounds in a system amenable to manipulation and observation.
Keywords: Alzheimer’s disease, Amyloid, Synapses, Organotypic brain slice, Intraneuronal Aβ, TgCRND8
Background
The progressive, permanent loss of neurons in Alzhei-
mer’s disease (AD) means the potential for effective
intervention declines as the disease advances [1]. Exam-
ining AD pathology at a late stage also makes identifying
the primary drivers of the disease cascade challenging,
as pivotal processes are masked by a melee of down-
stream consequences [2]. Taken together, it is clear that
for effective therapeutics to be developed, we must ob-
serve, and target, the disease in its initiating phase.
Synaptic dysfunction has long been noted as one of the
earliest hallmarks of AD [2], occurring in advance of
neuronal death [3, 4] and correlating best with soluble,
rather than plaque-forming, Aβ [5]. Within as little as
2 years of clinical onset, cortical synapse density can be
reduced by 35 % in patients [6], such loss of synapses
being the best correlate of clinical outcome [7]. Pre-
synaptic terminals seem especially vulnerable at this
stage; synaptophysin [8], rab3a [9, 10], and synaptobre-
vin [10] are all significantly depleted in early AD brain
tissue [11]. Despite other limitations, familial AD (FAD)
mouse models recapitulate the synaptic alterations of
the early stages of AD. As in human patients, there
is a plaque-independent loss of synaptophysin-
immunoreactive presynaptic boutons [12–14] as well as
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disruption of essential presynaptic components within
early dystrophic axons [15]. Direct readouts of synaptic
function also reveal deficits; LTP showing more rapid
decay in FAD mice [16]. Such alterations occur in
models lacking tau pathology, demonstrating alterations
in Aβ processing, at least in the presence of wild-type
murine tau [17], are sufficient to cause some synaptic
deficits.
Investigation of the relationship between Aβ and early
synaptic deficits would be facilitated by a model system
amenable to repeated sampling, imaging and manipula-
tion. While outer cortical layers of FAD mouse brain can
be imaged using a cranial window [18, 19], key areas of
pathology such as the hippocampus cannot. Instead, a
major, terminal operation is needed to reach them, limit-
ing observations to a single occasion [20]. Delivery of
drugs is also limited by the blood brain barrier or by the
acute and invasive nature of intracerebroventricular de-
livery. In vitro models, particularly of primary cortical
neurons, bypass many of these issues, but fail to account
for the complexity of the mammalian brain, its specia-
lised neuronal circuits and variety of interacting cell
types. Organotypic Hippocampal Slice Cultures (OHSCs)
fill an important gap between these two systems. Whilst
maintaining a complete hippocampal circuit and associ-
ated cell populations for several weeks, they allow for a
level of experimental manipulation and accessibility that
is unobtainable in vivo [21]. Screening for potential
disease-altering compounds is made easier by the lack of
blood-brain barrier or any systemic effects, and the abil-
ity to completely alter the extracellular environment in a
matter of seconds. By adding (or removing) test com-
pounds at different time points, their ability to prevent,
halt or reverse pathology can be easily assessed. As such,
OHSCs present an ideal platform to both observe and
manipulate the amyloid cascade.
OHSCs from FAD mice have been surprisingly under-
used in the AD research field, especially to study progres-
sive pathology caused by endogenously produced Aβ.
Some studies have focused on applying synthetic Aβ (in
various aggregation states) to acute cultures from non-
transgenic animals. Such work has highlighted the import-
ance of oligomeric Aβ in AD pathology, due to its en-
hanced ability to suppress of LTP [22], cause neuronal
death [23] and alter dendritic spine density [24]. Other
work has focussed on understanding plaque formation
and dissolution, showing, for example, that microglia from
adult FAD mice (when compared to juveniles or WT con-
trols) are ineffective at clearing synthetic Aβ fibrils [25],
and that neprilysin, insulysin and matrix metalloprotein-
ases can aid clearance of plaques already present in slices
prepared from adults [26]. Occasional studies using
OHSCs from FAD mice have used a single timepoint to
focus on dendritic spine or branching alterations following
transduction with human tau [27, 28] or manipulation of
tau pathology through pharmacological means [29]. There
is also little known about presynaptic pathology in
OHSCs, despite reports of extensive axonal swelling and
synaptophysin depletion in FAD mice in vivo [15, 30] and
in patients [31].
Here we describe an OHSC model from TgCRND8
mice [32] as a tool to explore the early and progressive
effects of Aβ in central nervous system (CNS) tissue. We
used this strain because amyloid pathology and axonal
swelling begin within two months in vivo [15]. This is
broadly within the timeframe for which OHSCs can be
maintained [33], so we hypothesised that early stages of
pathology caused by endogenous APP processing prod-
ucts should be detectable. We show that the transgenic
slices are viable for in excess of 8 weeks, retain all major
CNS cell types and rapidly release soluble Aβ into the
culture medium, the production rate of which can be
manipulated pharmacologically. While there is no plaque
pathology, there is a striking accumulation of intraneur-
onal Aβ (at least some of it axonal), far more than in
vivo, accompanied by a specific and progressive decline
in presynaptic proteins. This is now an excellent experi-
mental model for understanding the mechanism of pro-




TgCRND8 mice [32], overexpressing human APP with
Swedish (K670N/M671L) and Indiana (V717F) FAD mu-
tations, were maintained as heterozygotes on a 62.5:37.5
sv129: C57BL/6 background, generating transgenic and
wild-type (WT) littermate controls. Thy1-mitoCFP [34]
mice were also maintained as heterozygotes on a
C57BL/6 background and females were crossed with
TgCRND8 males to generate double transgenic mice.
Animals were kept on a 12:12hs light: dark cycle at a
constant temperature of 19 °C in a pathogen-free envir-
onment. All animal work was approved by the Babraham
Institute Animal Welfare and Ethical Review Body and
UK Home Office, and carried out in accordance with the
Animals (Scientific Procedures) Act, 1986, under Project
Licence 70/7620.
Organotypic slice cultures
Organotypic cultures of the hippocampus and surround-
ing cortex were taken from humanely sacrificed P6-P9
mouse pups of either sex according to the method de-
scribed by de Simoni et al. [33]. Briefly, brains were rap-
idly removed and kept in dissection buffer (EBSS+
25 mM HEPES+ 1 X Penicillin/Streptomycin) on ice.
From this point, until plating, all equipment and tissue
was kept ice cold. Brains were bisected at the midline
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then the cut sides glued (Loctite), face down onto a
vibratome stage and flooded with dissection media.
350 μm sagittal slices (6 per brain) were taken using a
Leica VT1000S Vibratome; the hippocampus with sur-
rounding cortex was dissected out using sterile syringe
needles whilst the slice was lying on the vibratome blade.
The dissected slices were then transferred (using a sterile
3 ml plastic pipette- modified to widen the opening) to
Falcon tubes full of ice-cold dissection medium and
stored until plating. To plate, slices were transferred (3
slices from the same brain per dish) onto sterile 0.4 μm
pore membranes (Millipore PICM0RG50) in 35 mm cul-
ture dishes (Nunc). Inserts were kept in 1 ml of main-
tenance medium (50 % MEM with Glutamax-1 (Life
Tech:42360-024), 25 % Heat-inactivated horse serum
(Life Tech: 26050-070 ), 23 % EBSS (Life Tech: 24010-
043), 0.65 % D-Glucose (Sigma:G8270) , 2 % Penicillin-
Streptomycin (Life Tech: 15140-122)and 6 units/ml Ny-
statin (Sigma: N1638) )and cultures were maintained in
incubators at 37 °C, 5 % CO2 for up to 12 weeks. Two
100 % medium exchanges occurred (5 hs after plating
and 4 div) and a 50 % media exchange occurred each
week thereafter.
Aβ ELISA and drug treatments
To determine levels of human Aβ1-40 or Aβ1-42 in the
slice culture medium, samples were analysed using com-
mercially available ELISA kits (Life Tech: KHB3441/
KHB3481). Briefly, culture medium was diluted to bring
the expected concentration within the range of the
standard curve before being incubated with Aβ detection
antibody for 3 hs at room temperature. After washing,
samples were incubated with HRP-conjugated anti-
rabbit antibody for 30mins, washed, and then incubated
with stabilised chromogen for 30mins. The reaction was
stopped using an acid-based stop solution and absorb-
ance read at 450 nm using a PheraStar FS plate reader.
Samples were run with a standard curve (4-parameter
fit) to obtain a concentration readout in pg/ml.
For quantifying Aβ within the slice tissue, material
from a single culture membrane (3 slices) was homoge-
nised in 10 μL 5 M Guanidine Hydrochloride supple-
mented with 1x Protease Inhibitor Cocktail (Roche) for
3-4 hs at room temperature (RT). The sample was then
frozen at -20 °C until use. Prior to running in the ELISA,
the homogenate was diluted 1:50 in ice cold reaction
buffer (Dulbecco’s PBS + 0.03 % Tween + 5 % BSA sup-
plemented with 1x Protease Inhibitor Cocktail) and cen-
trifuged for 20mins at 4 °C at 16,000 x g. The
supernatant was then diluted before undergoing ELISA
readout as for the media samples. Readout is given as pg
of Aβ per slice.
To determine how drug treatment influenced Aβ accu-
mulation, slices were moved to fresh maintenance media
for 24 hs. 50 μl of conditioned culture medium was then
taken and frozen at -20 °C to act as baseline production
readout. Calpain Inhibitor 1 (Sigma: A6185)) or DMSO
control was then applied to the culture, with 50 μl of the
treated medium dropped onto the slices to ensure
complete drug infusion. The medium on top rapidly
soaks through the slice, so the oxygen exchange is not
hindered during this time. 50 μl aliquots of culture
medium are then taken every 24 hs to monitor Aβ pro-
duction, with readouts normalised to the original 24 h
baseline. All drug experiments were run in triplicate,
with 3 independent membranes from different mice used
per experiment.
Immunofluorescence staining
Membranes were transferred into 6 well plates and slices
were fixed for 20mins in 4 % paraformaldehyde in 0.1 M
PBS (applied both above and below the membrane in-
sert). To reduce the volumes required for subsequent
steps, the membranes were cut free of the plastic inserts
and the sections of membrane containing the slices were
transferred, using forceps, to individual wells in a 24 well
plate. Slices were washed twice in TBS, blocked for 1 h
in blocking solution (TBS with 0.5 % Triton X-100 and
3 % Goat Serum) then incubated in 200 μl primary anti-
body diluted in blocking solution overnight at 4 °C with
shaking. Slices were washed 3 times in TBS before being
incubated (2 hs, RT in the dark) with Alexa488, 568 or
647 conjugated secondary antibodies (Life Technologies-
diluted 1:250 in blocking solution). After a final 3 TBS
washes, some slices were counterstained with Thioflavin
S, BTA-1, Nissl or Hoechst. Images were captured using
a Nikon Confocal Microscope. Primary antibodies used:
mouse Tuj1 (Covance 1:1000), rabbit Tuj1 (Sigma
1:500), chicken Tuj1 (Abcam:1:1000) rabbit NFL (Milli-
pore 1:250), mouse MOAB2 (pan specific to Aβ- Milli-
pore 1:1000), rabbit GFAP (Abcam 1:1000), mouse
synaptophysin (Dako 1:1000), rabbit PSD95 (Abcam
1:500), rabbit tau (Dako 1:1000), rabbit Iba1 (Wako
1:500) rabbit calbindin and rabbit parvalbumin (Kind
gifts from Dr P Emson 1:1000).
Quantification of Aβ positive swellings
To quantify the degree of Aβ positive swellings in
OHSCs of different ages, x20 images of MOAB2 staining
in the CA1 region were captured (blinded to culture age
and using identical microscope settings for each image)
then processed using Fijix64 image analysis software
[35]. The MOAB2 (red) channel was isolated and the
image threshold manually adjusted to remove back-
ground (thresholding was performed blind to culture
age, with the original image open in parallel, to ensure
the thresholded image accurately represented visible
staining). The plugin “despeckle” was applied to remove
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isolated pixel noise before the “Analyze particles” plugin
was run. “Total particle count” results were compared
between slices of different ages.
Synaptic marker image capture, processing and puncta
quantification
5-week old TgCRND8 and WT slices were imaged ac-
cording to the synapse quantification protocol adapted
from Ippolito and Eroglu [36–38]. Briefly, slices were
stained for PSD95 (secondary labelled Alexa-568) and
Synaptophysin (secondary labelled Alexa-488) according
to the standard immunofluorescence protocol described
above. Using a Zeiss 780 confocal x63 oil-immersion ob-
jective, image stacks from the CA1 (location of Aβ- posi-
tive axonal swellings in TgCRND8 cultures) and CA3
(largely swelling-free) fields were collected. For each
slice, the chosen field was imaged using serial optical
sections at 0.33 μm for a total of 15 sections (total depth
of 5 μm). Maximal intensity projections (MIPs) were
generated from 3 consecutive optical sections, resulting
in 5 images each displaying 1 μm depth per field section
in a slice. Quantification was performed using an imageJ
1.29 plugin [36, 39, 40] (available from c.eroglu@cellbio.-
duke.edu). Briefly, 33 μm x 33 μm regions of interest
were randomly selected from each MIP and the “Puncta
Analyzer” plugin run. Red (PSD95) and green (Synapto-
physin) channels were manually thresholded to highlight
visible puncta without the introduction of background
noise. The plugin provides quantitative data for puncta
number in each channel, as well as the number of colo-
calised puncta. 8 membranes per genotype (from differ-
ent mice) were analysed, the MIP values from individual
slices on the same membrane averaged to give an overall
“membrane average”. Throughout image collection and
analysis, the experimenter was blind to slice genotype.
Western blotting
Slices were scraped off the membrane, treated with 2x
Laemelli buffer + 10 % 2-mercaptethanol (250 μL per 3
slices) vortexed, boiled, then frozen at -20 °C until use.
For use, most samples were further diluted 1:2 and
loaded 8 μl per lane in a precast 4-20 % gradient gel
(Bio-rad). To detect the weaker signal for PSD95, 15 μl
of undiluted sample was loaded. After incubation in pri-
mary antibody overnight, blots were probed with 1:5000
mouse-700 (Life Technologies) and rabbit-800 (LI-COR)
secondary antibodies then imaged using a LI-COR
Odyssey detection system. Band intensity (IKK) was
quantified using Odyssey software then normalised to
Tuj1 signal. Primary antibodies used: mouse synaptophy-
sin (Abcam: 1:1000), rabbit tuj1 (Sigma: 1:2500), rabbit
PSD95 (Abcam: 1:500), mouse VAMP2 (Synaptic Sys-
tems: 1:10,000) and mouse RT97 (Kind gift from Dr
Diane Hanger 1:500). Tuj1-normalised protein
expression was then compared between WT and
TgCRND8 cultures, TgCRND8 values expressed as a per-
centage of the WT average.
Statistical analysis
Analysis was conducted using GraphPad Prism software.
To assess calpain inhibitor dose response and Aβ swell-
ing count data, one way ANOVAs with Dunnett or
Tukey post hoc tests (respectively) were used. For synap-
tic protein western blot and calpain inhibitor treatment
effects, two way ANOVAs with Sidak post hoc tests were
conducted. For synaptic puncta counts, Student’s t-tests
were used. Results are expressed as mean +/- standard
error.
Results
Slices from TgCRND8 mice survive in excess of 7 weeks in
vitro, demonstrate preserved architecture and possess
the expected range of cell types
To demonstrate that the major architecture of the
hippocampus is maintained throughout our experimen-
tal time-points, we fixed and stained slices at 7 weeks in
vitro. We found the dentate gyrus and CA1 to be re-
markably preserved in both WT (Fig. 1a) and TgCRND8
(Fig. 1b) cultures (as shown by Calbindin staining) with
clear axonal tracts seen projecting from the dentate
gyrus. Other major cell types are also well represented,
with microglia (Fig. 1c, d) and astrocytes (Fig. 1e, f )
clearly visible in both WT and transgenic slices.
Aβ1-42 is continuously released into the culture medium
By taking samples before each feeding time point, it can
be seen that Aβ1-42 is promptly released into the culture
medium. There is a rapid initial production of Aβ be-
tween plating and around 14 div (potentially due to the
inflammatory reaction to the slice preparation) where-
after the generation rate gradually slows, possibly reflect-
ing a decline in cell numbers not necessarily linked to
the transgene (Fig. 2a). A balance between Aβ1-42 pro-
duction and removal (through weekly 50 % medium ex-
change) is achieved between 14 and 42 div, resulting in a
consistent weekly fluctuation of between 5,000 and
10,000 pg/ml between feeds (final average concentra-
tion). No human Aβ1-42 is detected in WT slice medium
as expected (data not shown). This demonstrates that
the transgenic slices actively produce soluble Aβ1-42 and
are exposed to detectable levels throughout the culture
period (equivalent to around 1.1-2.2nM). The final aver-
age concentration can be increased by either reducing
the feeding frequency (we determined a 50 % medium
exchange each week to be optimal for allowing both
Aβ1-42 accumulation and adequate delivery of nutrients),
by increasing the number of slices plated per membrane
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(data not shown) or by pharmacological intervention
(below).
Aβ1-40 predominates in the culture medium, but the 42:40
ratio is higher in slice tissue
We compared the ratio of Aβ1-42 and Aβ1-40 in both
slice tissue and culture medium from TgCRND8 slices
(Fig. 2b). The Aβ1-42 isoform is generally considered
more pathogenic than Aβ1-40 and is the more abundant
of these two species in adult TgCRND8 mouse brain
[32]. As such, we were surprised to note that Aβ1-40 is
the predominant species within the slice culture medium
between 2 and 7 weeks in vitro. Interestingly, whilst
Aβ1-40 remains predominant in the slice tissue, the Aβ1-
42:Aβ1-40 ratio is significantly higher in slice tissue when
compared to the culture medium (p < 0.0001), with a
strong trend for this difference to increase with the age
of the slice (p = 0.055) . The higher Aβ1-42:Aβ1-40 ratio in
the tissue indicates that Aβ1-42 has a greater propensity
to be retained within the slice. This could be due to the
increased aggregation tendency of this isoform prevent-
ing escape into the medium. The Aβ1-42:Aβ1-40 ratio in
the slices is, however, still less than is seen at equivalent
timepoints in vivo (0.74 at 4 weeks, 0.93 at 6 weeks [32])
demonstrating a diversion from the in vivo pathogenic
time course. This could be seen as the slice modelling
only the earliest stages of the disease, or accumulation of
Aβ1-40 occurring more in slice medium due to lack of a
vascular system to clear it. We also found that the total







Fig. 1 OHSCs maintain hippocampal architecture and express a full complement of different cell types. a, b 7-week old WT (a) and TgCRND8 (b)
slices stained for Calbindin (green Alexa-488) and Tuj1 (red Alexa-568). Arrowheads show axons projecting from the dentate gyrus c, d 5-week old
WT (c) and TgCRND8 (d) slices showing microglia (Iba1- green Alexa 488) and nuclei (Hoechst- blue) e, f 7-week old WT (e) and TgCRND8 (f) slices
showing astrocytes (GFAP-red Alexa568) and nuclei (Hoechst-blue). Image locations, where appropriate, are denoted by the red ring on the
hippocampus diagram inset in each panel
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amount of Aβ detected in the medium (data not shown),
implying that any Aβ produced is very rapidly released
into the extracellular environment.
Intra-axonal Aβ accumulation in TgCRND8 slices
Previous studies indicate that intact axonal tracts are im-
portant for generation of Aβ [41, 42] and we reported a
close association between axonal swellings and amyloid
deposits as the disease progresses in mouse brain [15].
Thus, we then asked whether any of the Aβ present
within the slice tissue is located within axons, as a pos-
sible precursor of the Aβ in the slice culture medium
and of extracellular amyloid deposits in vivo. Immuno-
fluorescence revealed that many TgCRND8 cultures
a
b
Fig. 2 Measurement of Aβ in TgCRND8 slice culture medium and slice tissue. a Aβ1-42 concentration in the culture medium was measured over
time in vitro. Samples were first taken 4 days after plating, when medium was completely replaced (thick dashed line). At 7 div a further sample
was taken before a 50 % feed (thin dashed line). Samples were then taken at weekly intervals, shortly before each 50 % medium exchange. There
is a rapid rise in Aβ1-42 in the first 2 weeks in culture (shown by the gradient of the line between feeds), which slows after this point. Between 14
and 42 div production rate and removal are fairly well balanced, such that concentration lies between 5, 000 and 10,000 pg/ml between feeds.
This corresponds to 1.1-2.2nM Aβ1-42. (n = 5 membranes, each from a different mouse (biological replicates)) (b) Comparison of Aβ1-40 and Aβ1-42
in the culture medium and slices homogenised in 5 M guanidine. Whilst Aβ1-40 is the predominant species in both sample types, Aβ1-42: Aβ1-40
ratio is significantly higher in slice tissue than in the medium throughout the culture period (2 way ANOVA p < 0.0001) indicating a greater
proportion of Aβ1-42 is retained within the slice. There is a trend to this ratio difference increasing with age (2 way ANOVA p = 0.055). Star values
comparing slice tissue and culture medium represent multiple comparisons from the ANOVA analysis. (n = 4 membranes per timepoint/sample
type. Membranes in each timepoint were from different mice)
Harwell and Coleman Molecular Neurodegeneration  (2016) 11:44 Page 6 of 16
develop extensive accumulations of Aβ as detected by
MOAB2 (this antibody was specifically chosen as it is re-
ported not to detect APP [43]) in vitro) (Fig. 3a-c). This
is most abundantly seen in the regions adjacent to CA1
and is not seen in age-matched WT controls (Fig. 3d-f ).
Upon high magnification examination of the affected
areas in TgCRND8 cultures, it can be seen that this Aβ
staining colocalises with calbindin positive axonal swell-
ings in the alveus (an axonal tract formed by projections
from the cell bodies of CA1 [44–46]) (Fig. 3g-j). These
swellings are relatively large (between 5 and 20 μm);
much larger than the surrounding axon. There is no
colocalisation of these swellings with Hoechst, further
confirming (on top of their anatomical location) that
these structures are not cell bodies. We examined the
formation of these Aβ containing swellings in TgCRND8
cultures over time (Fig. 3k-n) and saw an increase in
number between 2 and 5 weeks in vitro (Fig. 3o). It is
important to note that WT slices also show calbindin
positive swellings in the same region but do not show
any sign of Aβ accumulation (Fig. 3d-f ).
Staining with thioflavin S or BTA-1 (a sensitive thiofla-
vin derivative) did not reveal convincing presence of
extracellular Aβ deposition or plaque formation up to
12 weeks in vitro (data not shown). This is in contrast to
the robust plaque development seen by 9 weeks in vivo
[32] which is not accompanied by extensive intracellular
Aβ staining. The conversion from extracellular to intra-
cellular Aβ accumulation in TgCRND8 OHSCs repre-
sents an important difference between this model and in
vivo.
The production of Aβ1-42 is increased by calpain
inhibition
As there was no spontaneous plaque development in
these OHSCs, we looked for ways to induce formation.
We first sought to enhance the production of Aβ1-42
using one of the key advantages of slice cultures over in
vivo models: the relative ease with which drugs can be
delivered. A number of compounds were tested of which
leupeptin, 27-hydroxycholesterol and LPS showed no
consistent effect (data not shown). However, Calpain In-
hibitor 1, which has previously been shown to increase
Aβ production in APP overexpressing 293 cells [47], was
more effective. We devised a protocol (Fig. 4a) that al-
lows differences in Aβ production rate to be detected, by
ensuring individual slice data is normalised to a pre-
treatment baseline readout. Addition of Calpain Inhibi-
tor 1 (10 μM) to 4-week old TgCRND8 slices approxi-
mately doubled the accumulation of Aβ1-42 in the
culture medium relative to a DMSO control (p < 0.0001),
with differences being apparent from as early as 24 hs
after treatment (Fig. 4b). A dose-response curve in 2-
week old slices indicated that 20 μM was most effective
over 72 hs, whereas higher doses significantly reduced
detectable Aβ below that of untreated cultures (Fig. 4c).
However, no convincing plaque pathology was observed
even after several weeks of 20 μM Calpain Inhibitor 1
treatment (data not shown). Attempts to seed pathology
using exogenously applied synthetic Aβ also failed to
elicit plaque formation (data not shown).
TgCRND8 slices undergo age-dependent depletion of
presynaptic proteins
It is well established that synaptic deficits are one of the
earliest events in Alzheimer’s Disease [2], and oligomeric
Aβ is known to disrupt synapses [24, 48, 49]. Western
blotting of slice homogenates from slices at 2-7 weeks in
vitro (Fig. 5a, b) revealed a highly significant depletion of
the presynaptic marker synaptophysin (normalised to
the neuronal marker Tuj1) in TgCRND8 cultures when
compared to WT (p < 0.0001) (Fig. 5c) that appears to
worsen with the age of the slice (p = 0.054). VAMP2 was
also reduced in TgCRND8 cultures when compared to
WT (p = 0.0017) but the relationship with culture ages
was less clear (p = 0.23) (Fig. 5d). As no such depletion
was observed in the axon specific marker RT97 (p =
0.91) (Fig. 5e) or the post-synaptic marker PSD-95 (p =
0.53) (Fig. 5f ), this suggests the deficiency is specific for
presynaptic boutons rather than axons as a whole or
both synaptic compartments.
TgCRND8 slices show region specific reduction in
pre-synaptic puncta and in PSD95/SYP colocalisation
As the appearance of Aβ containing axonal swellings
correlates temporally with the loss of presynaptic pro-
teins seen by western blot, we asked whether synaptic
structures were specifically altered in the swelling-
affected regions. By imaging presynaptic (synaptophysin)
and postsynaptic (PSD95) puncta in both the CA1 (the
region where Aβ positive swellings are found) and CA3
(a region lacking such structures) fields, we compared
alterations in synaptic contacts (areas of co-localisation
between pre- and post-synaptic marker labelled puncta
[36, 50]). In the CA1 region (Fig. 6a, b) we found a sig-
nificant reduction, compared to age-matched WT con-
trols, in the number of pre-synaptic puncta in 5-week
old TgCRND8 slices (p = 0.025) (Fig. 6c) without a corre-
sponding decrease in PSD95 positive, post-synaptic
puncta(p = 0.25) (Fig. 6d). This translated to a reduction
in the number of PSD95/SYP colocalised puncta, con-
sistent with a possible loss of synapses (p = 0.038)
(Fig. 6e). In the CA3 region (Fig. 6f, g), no such alter-
ations were apparent in either presynaptic puncta count
(p = 0.48) (Fig. 6h), postsynaptic count (p = 0.69) (Fig. 6i)
or PSD95/SYP colocalisation (p = 0.75) (Fig. 6j). Thus,
the reduction in synaptophysin we observed in western














Fig. 3 (See legend on next page.)
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blots at least partially reflects losses in presynaptic
puncta within CA1.
Discussion
Here we describe how long term OHSCs from
TgCRND8 mice can be used as a model of Aβ pathology,
revealing novel aspects of the disease mechanism that
are not easily studied in vivo. We can now explore, in a
system highly amenable to manipulation and analysis:
release of Aβ, loss of presynaptic proteins, loss of SYP/
PSD95 colocalisation and the accumulation of intraneur-
onal Aβ. We have also seen that addition of calpain in-
hibitor 1 enhances Aβ production in this model,
potentially opening doors to examine how pathological
outcomes change with rising Aβ. Whilst the nature and
time course of pathology shows some interesting differ-
ences from that seen in vivo, long term OHSCs from
TgCRND8 mice represent an exciting new tool for re-
search into the early consequences of progressive accu-
mulation of Aβ and other consequences of APP
processing.
Loss of presynaptic proteins and puncta
correlates spatially and temporally with the
appearance of intraneuronal Aβ
Loss of presynaptic proteins is thought to be one of the
earliest (and most clinically relevant) changes in human
AD [2, 51] with some reports indicating it precedes ex-
tensive postsynaptic changes [52]. In TgCRND8 OHSCs,
the presynaptic proteins synaptophysin and VAMP2 are
depleted when compared to WT controls. This corre-
sponds to a region-specific loss of presynaptic puncta,
consistent with loss of synapses. Our finding that PSD-
95 protein and puncta are not depleted supports the
notion that presynaptic changes can precede other alter-
ations [52–54]. The preservation of axon-specific phos-
phorylated neurofilament also supports localised
changes in the immediate presynaptic compartment, and
not a wider loss of axons at this stage.
A key future direction will be to determine the cause
of the presynaptic changes in the TgCRND8 slices. As
plaques do not develop during the experimental time-
course (see below), they are not needed to drive synaptic
alterations. Indeed, the lack of tau pathology in
TgCRND8 mice also rules out neurofibrillary tangles as
a necessary cause of the presynaptic protein depletion
we see. Whilst the observed synapse effects are clearly
dependent on the huAPP transgene, it is important to
remember that OHSCs undergo a period of synaptic
reorganisation in culture following the significant tissue
injury at the time of slice generation that does not occur
in vivo. In WT rat OHSCs, it has been shown that
within the first 2 weeks in vitro, the maximal evoked
EPSP increases, plateauing between 10 and 15 days in
vitro, likely representing an increase in synaptic connec-
tions [55]. APP overexpression has been shown to have
a negative effect on synapse development in vitro [56,
57] so it is possible that the TgCRND8 slices have a re-
duced capacity for this repair that at least partly under-
lies the lower presynaptic protein levels.
A clear difference between the WT and TgCRND8
OHSCs that associates both temporally and spatially
with the synaptic changes is the gradual appearance of
Aβ-containing swellings, most commonly located in the
alveus adjacent to CA1. There is an increase in the pres-
ence of such structures between 2 and 5 weeks in vitro,
which closely parallels the development of presynaptic
protein deficiency. The loss of synaptic structures, as
measured by PSD95/SYP puncta colocalisation, also
spatially correlates with the regions affected by Aβ posi-
tive swellings. Previous studies have shown that intra-
neuronal Aβ accumulation in synaptic compartments is
directly associated with abnormal cellular morphology
[58] whilst another study found that reducing the intra-
neuronal pool of Aβ through synaptic activation was
protective against loss of synaptic proteins [59]. The role
of intraneuronal Aβ in pathogenesis has been a contro-
versial topic [43, 60], so the experimental system we re-
port, in which Aβ generation and its release through
synaptic activity can be readily manipulated, will be use-
ful in resolving its importance in the disease process.
Intraneuronal Aβ in axonal swellings
Whilst many FAD mouse models have been reported to
develop pre-plaque intraneuronal Aβ pathology, [60–63]
it is particularly interesting that the appearance of such
(See figure on previous page.)
Fig. 3 Intraneuronal Aβ accumulation in axons projecting from CA1. Where appropriate, image locations are denoted by the red ring on the
hippocampus diagram inset in each panel. a-c Accumulation of Aβ in the CA1 region of a 5-week old TgCRND8 slice (d-f) no such Aβ staining is
apparent in the same region in WT slices. g-j High magnification imaging of the Aβ containing region in a 6-week old old TgCRND8 slice. The cell
bodies of CA1 (stained with calbindin) lie below the dashed line in these images. There is no strong colocalisation of Aβ with calbindin in this
region, and no colocalisation with Hoechst, demonstrating lack of Aβ within the cell bodies of CA1. Above the dashed line lies the alveus, an
axonal tract containing calbindin positive axons derived from CA1 (h). Many of these axons have large swellings, which do not colocalise with
Hoechst (demonstrating these swellings are not cell bodies). There is however extensive colocalisation of these axonal swellings with Aβ (i) as
indicated by the arrow heads. k-n 2,3, 4 and 5-week old TgCRND8 slices stained with MOAB reveal a progressive accumulation of Aβ positive swellings.
o Quantification of Aβ positive swellings (total count) in 2-5-week old old slices. There is a significant increase in these structures over time (1 way
ANOVA p < 0.05, n = 12 slices per timepoint (3 slices per mouse))
Harwell and Coleman Molecular Neurodegeneration  (2016) 11:44 Page 9 of 16
ab
c
Fig. 4 Treatment with Calpain Inhibitor 1 increases Aβ accumulation in TgCRND8 slice culture medium (a) Protocol for testing the effect of drug
treatments. The slice membrane is placed in fresh maintenance medium and left for 24 hs. A 50 μL sample of medium is then taken to act as a
“24 h baseline production” readout. Calpain Inhibitor 1 (or DMSO control) is then added to the culture, with treated medium allowed to soak
through the slice from above. Timepoints are then taken at 24, 48, 72 and 150 hs post treatment and normalised to the 24 h baseline readout.
(b) 10 μM Calpain Inhibitor 1 increases Aβ accumulation in slice culture medium to almost double that of control. (2 way ANOVA p < 0.0001(Large
bar above) (stars on graph represent significance between treated and untreated at each timepoint via ANOVA multiple comparisons). Results are
pooled from 3 independent experiments. n = 9 membranes per treatment (2 membranes arise from each mouse and are split between treated
and control, so all samples within a condition are from different animals) (c) By changing dosage of Calpain Inhibitor 1 and sampling at 24 h
baseline, then 72 h post treatment, a dose-response curve is revealed; 20 μM giving peak production, whilst concentrations above 40 μM reduce
Aβ production to below that of control levels (1 Way ANOVA p < 0.05 (stars represent significant deviation from 0 μM treatment) n numbers:
0 μM= 11, 5 μM= 5, 10 μM= 12, 20 μM= 12, 40 μM= 5, 50 μM= 2, 80 μM= 3, 100 μM= 3. (Note n numbers are lower above 40 μM due to
increased off-target toxicity in the culture system. All membranes used in each dose condition originated from different animals))






Fig. 5 Quantification of synaptic protein levels using Western Blot. a, b Representative Western Blot of 2-7-week old WT and TgCRND8 slices probed
for RT97 (phosphorylated neurofilament), Tuj1, Synaptophysin (SYP) and VAMP2 (a) or PSD95 and Tuj1 (b). c Synaptophysin levels (normalised to Tuj1)
are decreased in TgCRND8 relative to WT (two way ANOVA p < 0.0001). There is a trend to this difference increasing with culture age (two way ANOVA
p = 0.054), with 6 and 7-week old TgCRND8 cultures showing the greatest deficiency in synaptophysin (two way ANOVA multiple comparisons p <
0.05). d VAMP2 is also decreased in TgCRND8 cultures (two way ANOVA p = 0.0017) although the relationship with age is not clear (p = 0.23). There is
no alteration in the levels of phosphorylated neurofilament (p = 0.91) (e) or PSD95 (p = 0.53) (f) demonstrating the losses seen are likely specific to
presynaptic compartments. The large bar at the top of each graph displays tabular results from the two way ANOVA whilst individual bars on the
graph show significant multiple comparisons. N numbers are written in the base of each bar, and represent the number of individual membranes
(consisting of 3 slices extracted together and run in a single gel lane) from different mice










Fig. 6 (See legend on next page.)
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striking Aβ positive swellings in TgCRND8 OHSCs dif-
fers from the corresponding in vivo phenotype in these
animals. Whilst adult TgCRND8 mice usually show APP
immunoreactivity within dystrophic axons [15] and there
is some evidence for lysosomal Aβ accumulation in older
mice [64], extensive intra-axonal accumulations such as
the ones found in the OHSCs are not seen at any age
studied in this strain [15] (Additional file 1: Figure S1).
Interestingly, a similar phenomenon has been reported
in whole brain slices from adult APP_SDI mice; a failure
to develop plaques, but appearance of atypical intraneur-
onal Aβ staining [26]. This suggests that a hippocampus
in slice culture is more prone to retain Aβ within cells
than in vivo so it will be interesting to investigate the
mechanism that underlies this difference. The appear-
ance of swellings in WT cultures (albeit without Aβ ac-
cumulation) could indicate this is a result of axonal
damage during the slice procedure, or another conse-
quence of the slice culture system. Similarly, intraneuro-
nal Aβ accumulation is commonly observed in axonal
injury after brain trauma. Studies in humans [65], pigs
[66] and rats [67] have all reported that injured, swollen
or broken axons can act as sites of Aβ accumulation-
particularly in axonal end bulbs. The nature of the
OHSC is such that axotomy of certain populations of
neurons is unavoidable. Whilst there is evidence for re-
organisation and recovery in this model [68], it may be
that in the TgCRND8 cultures (which will already have
elevated levels of both APP and Aβ) this injury further
seeds accumulation of Aβ. However, as it takes over
3 weeks for the intraneuronal Aβ to accumulate, any link
to the initial injury appears likely to involve additional
steps.
A further possibility is, due to lack of sequestration in
plaques, the OHSCs may be bathed in relatively high
concentrations of soluble Aβ when compared to adult
brain. There is evidence to suggest that neurons can ac-
tively uptake Aβ, with the axon being highlighted as a
potential point of entry [69]. Indeed, application of syn-
thetic Aβ to OHSCs from WT rats resulted in intraneur-
onal accumulation of this peptide in CA1 [70], the same
region that is heavily affected in our TgCRND8 OHSCs.
Perhaps this region is rendered more vulnerable during
the slice procedure resulting in enhanced uptake of ex-
ogenous Aβ than would be seen in vivo.
Whatever the cause of the intraneuronal Aβ accumu-
lations in OHSCs, the fact that it differs from the in vivo
phenotype will help us to understand the factors that
govern the balance between intracellular and extracellu-
lar amyloid pathology. By studying the balance between
Aβ in the tissue and the medium it should also be pos-
sible to investigate factors that influence its rate of ex-
trusion. As both aspects of pathology are present in
sporadic human AD [58, 71, 72] understanding the
mechanisms of each could assist in developing effective
therapeutic interventions.
TgCRND8 OHSCs do not develop plaques
An unexpected finding in TgCRND8 OHSCs is that pla-
ques fail to develop even after 12 weeks in vitro, over 4
weeks after such pathology would develop in vivo [15,
32]. A potential explanation for this is that the large vol-
umes of culture medium relative to the small quantity of
slice tissue washes Aβ from the slices more effectively
than vascular perfusion, preventing the seeding of pla-
ques. Alternatively, it could be that the microglia in the
OHSCs are more effective at preventing plaque forma-
tion, perhaps as a result of activation from the initial
slice preparation. A recent paper demonstrated that
microglia from juvenile 5xFAD mice or WT controls are
highly effective at clearing synthetic Aβ fibrils applied to
WT OHSCs, whilst adult 5xFAD microglia cannot pre-
vent the formation of aggregates [25]. It may be that in
the long term OHSCs, a more juvenile microglial pheno-
type is maintained, thus preventing plaque deposition.
Understanding exactly how the slice system differs to in
vivo will, once again, assist in unpicking the mechanisms
behind AD pathology.
A model for studying pre-plaque Aβ dynamics
Whilst plaque development is not observed, TgCRND8
OHSCs’ rapid and sustained production of soluble Aβ
peptides is easily detected. This system is ideal for exam-
ining the effects of early rises in Aβ on the hippocampus
in a pre-plaque forming stage. We have also demon-
strated that the production rate of Aβ in OHSCs can be
(See figure on previous page.)
Fig. 6 Region specific pre-synaptic puncta loss in TgCRND8 slices. a, b Representative maximal intensity projections of z-stacks taken from the
CA1 field (same location as Aβ positive axonal swellings) in 5-week old WT (a) and TgCRND8 (b) slices. The presynaptic marker synaptophysin
(SYP) is stained green, whilst the postsynaptic marker PSD95 is stained red. c, d, e Quantification of the z-stacks was performed using an image
J plugin (available on request from: c.eroglu@cellbio.duke.edu). There was a reduction in synaptophysin positive puncta in TgCRND8 slices
(p = 0.025) (c) whilst the number of PSD95 positive puncta was unchanged between genotypes (p = 0.25) (d). The number of colocalised puncta
(Synaptophysin/ PSD95 positive) was also reduced (p = 0.038) (e). f, g Z-stacks taken from the CA3 field (largely unaffected by Aβ-positive swellings) in
5-week old WT (f) and TgCRND8 (g) slices revealed no such differences in synaptophysin positive puncta (p = 0.48) (h), PSD95 (p = 0.69) (i)
or colocalised structures (p = 0.75) (j). Analysis for each region consisted of n = 8 individual membranes, 3 slices per membrane (slices on
each membrane are from different mice). For each membrane value, data was averaged from 3 slices, with 5 z-stacks per slice) with P
values calculated using a students t-test
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bidirectionally manipulated through pharmacological
means. Addition of 20 μM Calpain Inhibitor 1 doubles
Aβ in the medium relative to control, whilst addition of
50 μM or more supresses production (consistent with
previous findings in APP transfected 293 cells [47]).
Whilst therapies would seek to reduce the rate of accu-
mulation of Aβ there are clear experimental advantages
in being able to increase its generation to explore mech-
anisms in a model system. As well as potentially permit-
ting earlier observation of defects in culture, it allows
determination of whether the severity directly correlates
with soluble Aβ concentration in the environment or
whether changes proceed to completion after Aβ passes
a threshold level. This distinction is vital for effective
therapeutic targeting.
Additional uses of the model
The OHSC model we describe has many potential uses in
studying the mechanism of amyloid pathology and devel-
oping therapeutics, but also a number of limitations. Slice
preparation involves massive tissue damage, resulting in
axotomy, cell death and activation of inflammatory cells.
Plaque pathology does not develop, and there is increased
intra-axonal Aβ beyond that seen in vivo. There is also a
gradual over proliferation of non-neuronal cells, no vascu-
lar system and no electrical input from other brain re-
gions. It should also be remembered that the slices are
generated from juvenile mice, where many cells have yet
to reach their mature phenotypes.
However, the progressive changes we report in long
term TgCRND8 OHSCs have significant potential to be of
use to the AD research field. For example, the rapid pro-
duction of soluble Aβ species from these slices could be
utilised as a source of pathogenic amyloid peptides with-
out presupposing which of them is/are the most toxic.
These could then be introduced exogenously into other
experimental systems such as primary neuronal cultures,
or OHSCs of a different genotype, avoiding the use of
supraphysiological concentrations of synthetic peptides.
This system should also enable studies examining the
spread of pathological proteins, and screening, at least at a
secondary stage, for compounds that will block Aβ gener-
ation or release, or block synaptophysin depletion.
The ability to repeatedly image, or live image, OHSCs
is also important. Unlike the in vivo hippocampus,
which is difficult to image even using multiphoton mi-
croscopy, we have been able to observe live cells such as
microglia (stained using isolectin B4 conjugated to Alexa
fluora568 (Life Technologies)) (Additional file 2: Figure
S2a) and the axonal transport of mitochondria in
OHSCs expressing mito-CFP (Additional file 3). We find
that axons from the dentate gyrus are easily located with
this genetic label (Additional file 2: Figure S2b-c) and
repeat imaging of the same slices is possible.
Mitochondrial or other axonal transport dynamics have
been implicated many times in the pathogenesis of AD.
Further work will be needed to develop this transport
imaging for quantitative assessment, but probing for dif-
ferences in the TgCRND8 slices has the potential to en-
hance understanding in a way that would not be possible
in vivo.
Conclusions
In summary, we report the first characterisation of
progressive deficiencies in OHSCs from a huAPP
mouse model. This reveals both similarities and dif-
ferences from observations made in the same mouse
strain in vivo, thus validating this system as a model
for some aspects of pathogenesis. The model will be
particularly useful for understanding disease mechan-
ism, both because it can be readily manipulated, re-
peatedly sampled and imaged, and because the
observed differences from in vivo pathology provides
a basis for understanding why these occur (for ex-
ample, the shift from plaques to intraneuronal Aβ).
This experimental system also has important potential
as a drug-screening platform. Here, candidate drugs
can be readily delivered and monitored, and their ef-
fects on all relevant cell types and neuronal circuits
observed, thus filling a vital gap between primary cul-
ture and in vivo studies. We expect this OHSC model
will find many applications in AD research.
Additional files
Additional file 1: Figure S1. MOAB2 immunostaining in a 14 month
old TgCRND8 hippocampus. Aβ in extracellular plaques is stained using
the MOAB2 antibody (a) and neurons in CA1 stain positively for calbindin
(b) but there is no evidence for intra-axonal Aβ in the merged image (c).
(PPTX 3615 kb)
Additional file 2: Figure S2. Demonstrations of live imaging capability in
the TgCRND8 OHSC system. Live microglia labelled with IB4 conjugated to
Alexa 568 (a) Mito-CFP labelling in TgCRND8x MitoP OHSC (b). The dentate
gyrus and axons projecting from it are clearly labelled. Multiphoton image
of MitoCFP labelled neuron in OHSC (c). (PPTX 749 kb)
Additional file 3: Live axonal transport of mitochondria in a TgCRND8x
MitoP OHSC. (1 frame per second capture rate, 80 frames per second
playback rate). (AVI 9113 kb)
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